The Economic Burden of Inflammatory Arthritis: A Systematic Review

Xiaoyu Zhang (), Jiaru Liu (), Zhengwei Wang (), James Galloway (), Sam Norton (), Sumeet Singla () and Huajie Jin ()
Additional contact information
Xiaoyu Zhang: King’s Health Economics, Institute of Psychiatry, Psychology and Neuroscience at King’s College London
Jiaru Liu: King’s College London
Zhengwei Wang: King’s Health Economics, Institute of Psychiatry, Psychology and Neuroscience at King’s College London
James Galloway: King’s College London
Sam Norton: Medical Statistics and Applied Health Research, Centre for Rheumatic Diseases, King’s College London
Sumeet Singla: Maulana Azad Medical College and Associated Lok Nayak Hospital
Huajie Jin: King’s Health Economics, Institute of Psychiatry, Psychology and Neuroscience at King’s College London

PharmacoEconomics, 2025, vol. 43, issue 12, No 2, 1389-1403

Abstract: Abstract Background and Objective Inflammatory arthritis is a common condition treated in rheumatology clinics, contributing significantly to healthcare costs and societal burden. Understanding the economic impact of inflammatory arthritis requires a comprehensive analysis through cost-of-illness studies. This systematic review aims to gather up-to-date cost-of-illness data on inflammatory arthritis from various countries, identify the primary cost drivers, describe shifts in cost components and appraise the quality of cost-of-illness study reporting in this field. Methods An electronic search was performed across four databases, including MEDLINE, Embase, the Cochrane Database of Systematic Reviews and the Health Management Information Consortium, to identify cost-of-illness studies on inflammatory arthritis published over the past two decades. The primary outcome was the annual cost per patient with inflammatory arthritis, categorised by cost components. All costs were standardised to 2024 US dollar values. The quality of the included studies was evaluated using the Larg and Moss checklist and the modified Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. Results From an initial 12,264 publications, 82 studies were included in this review, covering axial spondyloarthritis (n = 49), psoriatic arthritis (n = 30), reactive arthritis (n = 2), rheumatoid arthritis (n = 13; 2019 onwards) and seronegative/seropositive rheumatoid arthritis (n = 8). Annual total societal costs varied considerably across inflammatory arthritis subtypes and countries. Medication expenditures consistently emerged as the primary direct healthcare cost driver, while productivity losses due to morbidity constituted the major component of indirect costs. Carer productivity loss represented a substantial proportion of indirect costs (up to 60.9%), yet was infrequently reported. Over time, we observed an increasing proportion of medication-related costs and a decreasing proportion of productivity losses for axial spondyloarthritis, alongside a reduction in inpatient care costs for psoriatic arthritis. These evolving cost distributions mirror patterns previously reported in rheumatoid arthritis. Methodological gaps were evident, with most studies lacking sensitivity analyses and comprehensive cost perspectives. Conclusions A substantial economic impact of inflammatory arthritis across different regions and subtypes was identified. This review emphasises the importance of including comprehensive cost components to fully assess the economic burden of inflammatory arthritis and provides methodological recommendations for future studies.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-025-01534-8 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:43:y:2025:i:12:d:10.1007_s40273-025-01534-8

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-025-01534-8

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().